










































Are tangles as toxic as they look?
Citation for published version:
Spires-Jones, TL, Kopeikina, KJ, Koffie, RM, de Calignon, A & Hyman, BT 2011, 'Are tangles as toxic as
they look?' Journal of molecular neuroscience : MN, vol. 45, no. 3, pp. 438-44. DOI: 10.1007/s12031-011-
9566-7
Digital Object Identifier (DOI):
10.1007/s12031-011-9566-7
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of molecular neuroscience : MN
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Are Tangles as Toxic as They Look?
Tara L. Spires-Jones
Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA
02129, USA
Katherine J. Kopeikina
Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA
02129, USA
Department of Anatomy and Neurobiology, Boston University School of Medicine, 72 East
Concord Street (L 1004), Boston, MA 02118, USA
Robert M. Koffie
Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA
02129, USA
Alix de Calignon
Department of Physiology, Anatomy, and Genetics, University of Oxford, Parks Road, Oxford
OX1 3PT, UK
Bradley T. Hyman
Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA
02129, USA
Abstract
Neurofibrillary tangles are intracellular accumulations of hyperphosphorylated and misfolded tau
protein characteristic of Alzheimer's disease and other tauopathies. Classic cross-sectional studies
of Alzheimer patient brains showed associations of tangle accumulation with neuronal loss,
synapse loss, and dementia, which led to the supposition that tangles are toxic to neurons. More
recent advances in imaging techniques and mouse models have allowed the direct exploration of
the question of toxicity of aggregated versus soluble tau and have surprisingly challenged the view
of tangles as toxic species in the brain. Here, we review these recent experiments on the nature of
the toxicity of tau with particular emphasis on our experiments imaging tangles in the intact brain
through a cranial window, which allows observation of tangle formation and longitudinal imaging
of the fate of tangle-bearing neurons. Neurofibrillary tangles (NFT) were first described in 1906
by Alois Alzheimer based on Bielschowsky silver staining of the brain of his demented patient
Auguste D (Alzheimer 1907; Goedert and Spillantini 2006). These intraneuronal aggregates have
subsequently been found to be composed primarily of hyperphosphorylated tau protein and are
definitive pathological lesions not only in Alzheimer's disease but also in a class of
neurodegenerative tauopathies (Goedert et al. 1988; Spires-Jones et al. 2009). NFT pathology in
Alzheimer's disease (AD) correlates closely with cognitive decline and synapse and neuronal loss
(Braak and Braak 1997; Bretteville and Planel 2008; Congdon and Duff 2008; Mocanu et al.
2008b; Spires-Jones et al. 2009). As a result, NFT have long been considered indicative of
impending neuronal cell death. More recent evidence, however, opposes this classical view. Here
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we review evidence addressing the question of whether NFT cause structural or functional
neuronal damage.
Keywords
Tau; Alzheimer; Neurofibrillary tangle; Neurodegeneration
Classical View of Tangles as Toxic
Tau is a microtubule-associated protein (Goedert and Spillantini 2006; Selkoe 2001)
primarily expressed in the central nervous system. The tau protein has over 80
phosphorylation sites and is tightly regulated by protein kinases and phosphatases
(Bretteville and Planel 2008; Hyman et al. 2005; Spires-Jones et al. 2009). During disease
pathogenesis, normal tau becomes hyperphosphorylated, causing it to fall off the
microtubules and be relocated to the somatodendritic compartment (Bramblett et al. 1993;
Stoothoff and Johnson 2005). Here it is subjected to further phosphorylation and
conformational change, which leads to the formation of paired helical and straight filaments
of abnormal tau. These filamentous or fibrillar forms of tau aggregate into mature NFT
(Kuret et al. 2005).
It is indisputable that tau dysfunction can lead to neurodegeneration. While neurofibrillary
tau pathology in AD may be downstream of amyloid beta induced stressors, mutations in tau
can lead to autosomal dominant frontotemporal dementia and Parkinsonism linked to
chromosome 17 (Hutton 2001; Hutton et al. 1998). Overexpressing human wild-type or
dementia-associated mutant forms of tau also lead to neuronal death in cell culture,
drosophila systems, and in several transgenic mouse lines (Bulic et al. 2007; Hutton et al.
2001; Khlistunova et al. 2006; Shulman and Feany 2003; Spires and Hyman 2005;
Wittmann et al. 2001). While the mechanism of tau causing neuronal dysfunction and death
remains unclear, there is strong evidence that hyperphosphorylation, mislocalization to the
somatodendritic compartment, and aggregation all contribute.
Aggregation of tau into mature, silver-positive NFT has been thought to contribute to
neuronal loss in AD based on the close correlations between NFT pathology, both in terms
of location and number, and degree of AD severity and cognitive decline (Arriagada et al.
1992; Giannakopoulos et al. 2003; Gomez-Isla et al. 1996). It is important to note, however,
that neuronal loss exceeds NFT number by at least one order of magnitude and the two
become completely dissociated in several brain regions (Gomez-Isla et al. 1997;Terry 2000;
van de Nes et al. 2008;Vogt et al. 1998). In many of the mouse models that overexpress
FTD-associated mutant tau, NFT form in some of the same regions that undergo neuronal
loss (Allen et al. 2002; Andorferet al. 2005; SantaCruz et al. 2005; Spires et al. 2006;Zehr et
al. 2004), but it is unclear from these studies whether NFT play a role in cell loss. In fact,
markers of cell death were not found in NFT bearing neurons in htau mice (Andorfer et al.
2005), indicating that cell death occurs independently of NFT. Mandelkow et al. have shown
that in cultured cells, expression of an aggregate-prone tau construct is associated with cell
death (Khlistunova et al. 2006; Wang et al. 2007). This aggregate prone construct, however,
also caused toxicity before beta sheet conformational aggregates were detected using
fluorescence, indicating that a pre-fibrillar form of tau aggregate could be toxic (Khlistunova
et al. 2006). When expressed in a transgenic mouse line, the aggregate-prone deltaK280
mutant tau repeat domain construct was also more toxic than an anti-aggregate form of
deltaK280 tau repeat domain with two proline mutations, although both underwent tau
mislocalization to the somatodendritic compartment (Mocanu et al. 2008a). This implicates
tau aggregation in neurotoxicity.
Spires-Jones et al. Page 2













NFT-bearing neurons receive fewer synapses onto their soma assessed by EM in a mouse
model of tauopathy (Katsuse et al. 2006), which could contribute to neuronal loss due to
deafferentation. Synaptophysin mRNA and other classes of mRNA involved in synaptic
signaling and cytoskeletal maintenance are also decreased in NFT-bearing neurons in AD
brain (Callahan et al. 1999; Ginsberg et al. 2000), arguing a loss of connectivity of these
cells.
New Evidence Suggests Aggregated Tau may not be the Most Toxic
Species
Although NFT formation correlates to some extent with neuronal loss and cognitive decline
in AD, there is emerging evidence that the aggregated form of tau may not be the toxic
species. One line of evidence supporting this view comes from the studies of dysregulation
of axonal transport due to tau alterations. It is known that excessive tau levels can block
anterograde transport (Baas and Qiang 2005; Mandelkow et al. 2003; Stoothoff et al. 2009).
In reduced microtubule preparations, tau binding to microtubules causes kinesin to detach,
thus reducing anterograde transport (Dixit et al. 2008). Thus it is thought that normally, the
increasing gradient of tau distally down the axon causes synaptic proteins to detach from
microtubules as they reach the synapse, whereas in tauopathy, mislocalization to the soma
blocks kinesin binding to the microtubules and prevents it from initiating anterograde
transport. This being the case, aggregation of tau in the soma into filaments where it cannot
interfere with transport may be beneficial. Tau is also known to stabilize microtubules, and
the hyperphosphorylation during disease reduces tau binding to microtubules. Iqbal's group
showed that soluble hyper-phosphorylated tau sequesters normal tau, microtubule-associated
protein 1 (MAP 1) and MAP 2 in vitro, causing disruption of existing microtubules and
inhibition of microtubule assembly (Alonso et al. 1994, 1996;Iqbal et al. 2008). In 2006, this
group further demonstrated that sequestering soluble hyperphosphorylated tau into paired
helical filaments reduces the binding of hyperphosphorylated tau to normal tau and is a
defense mechanism to preserve normal transport (Alonso Adel et al. 2006).
Directly related to axonal transport deficits is regulation of mitochondrial distribution, which
is essential in neurons due to high energy demands and extended processes requiring
extensive organelle transport (Hollenbeck and Saxton 2005). Several studies in cultured
cells, including our own, show that tau overexpression impairs mitochondrial trafficking and
distribution, primarily by impairing their anterograde transport (Ebneth et al. 1998;Stamer et
al. 2002; Stoothoff et al. 2009). Tau phosphorylation by Cdk5 at position 231 is known to be
a prominent change in the AD brain and has been implicated in mitochondrial clustering
(Darios et al. 2005). In the AD brain, Wang et al. (2009) found evidence of impaired balance
of mitochondrial fission and fusion. In cultured neurons, they went on to show that similar
mitochondrial deficits could be induced with soluble amyloid beta treatment concomitant
with synaptic loss. In a more recent study, Zempel et al. (2010) extended this finding to
show that oligomeric amyloid beta induced loss of dendritic spines and mitochondrial
distribution correlate with mislocalization of tau to dendrites in cultured neurons. In a
separate study, caspase-cleaved tau was shown to lead to mitochondrial fragmentation
(Quintanilla et al. 2009). All of these studies showing mitochondrial distribution and fission/
fusion deficits link soluble, not fibrillar tau to mitochondrial deficits.
Soluble forms of tau have been found to correlate with neuronal and synaptic dysfunction in
several transgenic mouse models (Berger et al. 2007; Hoover et al. 2010; SantaCruz et al.
2005; Sydow et al. 2010). Berger et al. (2007) found a correlation between memory loss in
rTg4510 mice and accumulation of SDS-stable oligomeric forms of tau in the soluble (non-
NFT) fraction of brain tissue. In two different regulatable mouse models of tauopathy,
transgene suppression resulted in recovery of memory deficits despite the continued
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presence of NFT arguing against NFT as the tau species causing synaptic dysfunction
(SantaCruz et al. 2005; Sydow et al. 2010). Using the rTg4510 mouse model, Hoover et al.
(2010) found deficits in LTP and spatial memory before substantial neuronal loss. In
cultured neurons, they found that phosphorylated tau localized to dendritic spines where it
impairs synaptic function by decreasing the amounts of synaptic AMPA and NMDA
receptors. This study implicates hyperphosphorylated, not aggregated tau in synaptic
dysfunction, but NFT do not form in culture so they did not formally address whether NFT
also contribute to synaptic dysfunction in vivo. To directly assess whether NFT damage
neuronal function, Rocher et al. used slice electrophysiology to record from individual cells
with and without NFT in rTg4510 brain. They found that cortical neurons in rTg4510 mice
have depolarized resting membrane potential and increased evoked repetitive action
potential firing rates and concomitant structural degeneration of dendritic branching and loss
of dendritic spines. These functional and structural deficits did not vary between NFT and
non-NFT bearing neurons (Rocher et al. 2010), again implicating a soluble form of tau in
neuronal dysfunction and degeneration.
In terms of causing cell death, several studies in vitro have shown that nonaggregated forms
of tau, including oligomers and caspase-cleaved tau can be toxic (Chung et al. 2001;
Lasagna-Reeves et al. 2010). Some familial tau mutations that cause dementia have very
little aggregated tau pathology (Reed et al. 2001). Tau expression can also induce
neurodegeneration without NFT formation in Drosophila models (Shulman and Feany 2003;
Wittmann et al. 2001), indicating toxicity of a soluble form of tau. There is evidence of
dissociation of cell death and neurofibrillary pathology from transgenic mouse lines. The
rTg4510 mouse model reversibly expresses dementia associated P301L mutant human tau
and develops age-related NFT and neuronal loss (SantaCruz et al. 2005; Spires et al. 2006).
In this model, the CA1 region of the hippocampus undergoes both severe neuronal loss and
extensive NFT formation, however, most of the dentate gyrus granule cells die despite a lack
of NFT and the striatum has significant NFT formation without much neuronal loss,
indicating some dissociation between regions with NFT formation and neuronal loss (Fig.
1). Further, transgene suppression can prevent neuronal loss without affecting NFTs in
rTg4510 mice (Spires et al. 2006). In aggregate-prone tau repeat domain transgenic mice,
transgene suppression from 10 to 14 months reversed memory loss and LTP deficits without
removing most of the neurofibrillary pathology, indicating the presence of the pro-
aggregating tau protein but not the aggregates themselves contribute to dysfunction (Sydow
et al. 2010). Neuronal loss was not formally quantified in this study, but further neuronal
loss after transgene suppression may have also been prevented as seen in the rTg4510
model.
In Vivo Imaging Directly Addresses Whether Tangles Cause Cell Death
To directly observe NFT formation in the intact brain and whether this aggregation leads to
cell death, we developed a method using in vivo multiphoton imaging in the rTg4510
transgenic model of tauopathy. Multiphoton imaging through a craniotomy sealed with a
glass coverslip allows penetration of laser excitation deep into the neocortex, including
layers II–III which form NFT in the rTg4510 mice (Spires-Jones et al. 2011). This technique
requires introduction of a fluorophore to bind the structure of interest. In the case of NFT,
we first used thioflavin S (ThioS), which is known to bind amyloid fibrils including NFT. In
rTg4510 mice and mice injected with AAV encoding human tau, ThioS binding to NFT
occurs after mislocalization of tau to the soma and hyper-phosphorylation assessed using tau
and phospho-tau immunochemistry (de Calignon et al. 2010; Spires-Jones et al. 2008).
ThioS binding is also a later event than silver-positive staining of NFT, the classic marker
for a mature tangle, thus the staining we observe in vivo with ThioS represents true NFT
pathology. Topical application of ThioS (0.025% in sterile PBS) to the cortex after removing
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the meninges labels NFT in the living brain (de Calignon et al. 2010;Spires-Jones et al.
2008). ThioS does not cross the blood-brain barrier when administered systemically, and
topical application can only be performed at the time of cranial window implantation, so we
also developed the use of FSB and X-34, blood-brain barrier penetrating compounds first
used by Goedert's group to label NFT in mouse models (Velasco et al. 2008), to image NFT
after i.v. injection and observe similar clear labeling of NFT throughout the brain (de
Calignon et al. 2010). The use of these systemically administered dyes allows longitudinal
imaging of NFT to follow whether cells disappear after tangle formation. It is worth noting
that the appearance of ThioS or X-34 positive NFT is preceded by tau mislocalization,
phosphorylation, and misfolding that cannot be detected by amyloid binding dyes in vivo
but is readily observed postmortem with immunohistochemistry. Thus, we observe the last
step of mature tangle formation in vivo, likely after a critical number of filaments form in a
discrete cellular compartment allowing visualization with these dyes with 2-photon
microscopy.
Furthermore, we developed the use of fluorescent indicators of caspase activation in vivo to
test the hypothesis that the observed cell death in rTg4510 mice is a caspase-mediated
phenomenon. Using a combination of ThioS and a polycaspase indicator (red fluorescent
inhibitor of capases from Invitrogen), we observed that a subset of tangle-bearing neurons
contain active caspases and very rare non tangle-bearing neurons also show caspase
activation in these mice (Fig. 2). Surprisingly, caspase activation appears before NFT
formation when neurons contain soluble tau mislocalized to the soma. Neurons with active
caspases rapidly form NFT, over the course of hours, then these NFT bearing neurons
persist for days. Caspases ultimately must be deactivated in these cells since all newly
formed NFT have active caspases and only 5% of total NFT are positive for caspase
activation. Using Hoescht labeling, we confirmed that neuronal nuclei appear healthy and
intact the day after a new tangle forms (de Calignon et al. 2010). Postmortem, we have
found that rTg4510 mice do not develop “ghost” tangles, which has been confirmed with
electron microscopy in this model (Ludvigson et al. 2010), so the NFT that we follow for
several days in vivo are highly likelytobeliveneurons.
These in vivo data show that tangles form very rapidly downstream of caspase activation
and that these tangles do not cause the cell to die acutely, in fact, caspase activation is
reversed and cells live for at least 5 days. Based on these experiments, we postulate that
aggregated tau may not cause acute cell death but may in fact either be neutral or protect the
neuron in the short term from the toxic effects of soluble species of tau. This conclusion is
supported by transgene suppression data showing that lowering levels of soluble tau
prevents further neuronal loss in the face of continued presence and accumulation of NFT
(Spires et al. 2006). Future essential questions remain including which neurons are dying in
tauopathies. Tangle bearing neurons do not die acutely in the rTg4510 model, but does the
aggregate eventually cause impaired transport, protein degradation system breakdown, and
slow death? Longitudinal imaging of NFT with systemic administration of X-34 will allow
NFT to be followed long term, potentially throughout the lifetime of the animal, to
definitively address the question of whether tangle-bearing neurons eventually die. Or do
neurons with mislocalized, hyperphosphorylated, soluble tau that do not seed a tangle to
sequester toxic soluble species die? It is also important to elucidate the mechanisms of cell
death to develop therapeutic interventions.
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Some dissociation between NFT (brown) and neuronal loss (nuclei labeled blue with cresyl
violet) is observed in rTg4510 mice which have substantial neuronal loss in dentate gyrus
(arrows) despite very few NFT. CA1 (arrowheads) undergoes both NFT formation and
neuronal loss. Scale: 500 μm
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Caspase activation precedes NFT formation in rTg4510 mice as modeled ion (a). Tau
becomes hyperphosphorylated and mislocalized to the somatodendritic compartment.
Caspases are then activated and NFT form very rapidly. Since neurons with new NFT
survive at least 5 days and caspases are turned off, we postulate that NFT formation reduces
the toxic soluble hyperphosphorylated tau levels in the soma allowing caspases to become
deactivated preventing apoptosis. An example of caspase activation in vivo followed 24 h
later by a Thioflavin S positive tangle is shown in (b). Scale: 10 μm
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